ZA200905636B - Stable antibody formulations - Google Patents

Stable antibody formulations

Info

Publication number
ZA200905636B
ZA200905636B ZA200905636A ZA200905636A ZA200905636B ZA 200905636 B ZA200905636 B ZA 200905636B ZA 200905636 A ZA200905636 A ZA 200905636A ZA 200905636 A ZA200905636 A ZA 200905636A ZA 200905636 B ZA200905636 B ZA 200905636B
Authority
ZA
South Africa
Prior art keywords
antibody formulations
stable antibody
stable
formulations
antibody
Prior art date
Application number
ZA200905636A
Other languages
English (en)
Inventor
Arvind Srivastava
Joel Goldstein
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of ZA200905636B publication Critical patent/ZA200905636B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200905636A 2007-03-22 2009-08-13 Stable antibody formulations ZA200905636B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91974407P 2007-03-22 2007-03-22

Publications (1)

Publication Number Publication Date
ZA200905636B true ZA200905636B (en) 2010-10-27

Family

ID=39766776

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200905636A ZA200905636B (en) 2007-03-22 2009-08-13 Stable antibody formulations

Country Status (18)

Country Link
US (1) US20100260766A1 (xx)
EP (1) EP2136839A4 (xx)
JP (1) JP2010522208A (xx)
KR (1) KR20090113340A (xx)
CN (1) CN101668540A (xx)
AU (1) AU2008228823A1 (xx)
BR (1) BRPI0809112A2 (xx)
CA (1) CA2681743A1 (xx)
CR (1) CR11005A (xx)
DO (1) DOP2009000222A (xx)
EA (1) EA200970880A1 (xx)
EC (1) ECSP099642A (xx)
IL (1) IL200321A0 (xx)
MX (1) MX2009010179A (xx)
TN (1) TN2009000382A1 (xx)
UA (1) UA96473C2 (xx)
WO (1) WO2008116103A2 (xx)
ZA (1) ZA200905636B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
TW200838559A (en) * 2006-11-29 2008-10-01 Imclone Systems Inc Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
MX2011004558A (es) 2008-10-29 2011-06-01 Wyeth Llc Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio.
US9393304B2 (en) 2008-10-29 2016-07-19 Ablynx N.V. Formulations of single domain antigen binding molecules
CA2743469C (en) * 2008-11-12 2019-01-15 Medimmune, Llc Antibody formulation
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
UA105198C2 (ru) 2008-12-12 2014-04-25 Берингер Ингельхайм Интернациональ Гмбх Антитело против инсулиноподобных факторов роста
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
AR083035A1 (es) * 2010-09-17 2013-01-30 Baxter Int ESTABILIZACION DE INMUNOGLOBULINAS MEDIANTE UNA FORMULACION ACUOSA CON HISTIDINA A pH ACIDO DEBIL A NEUTRO, COMPOSICION ACUOSA DE INMUNOGLOBULINA
EP3757126A1 (en) 2010-11-05 2020-12-30 Novartis AG Methods of treating psoriatic arthritis using il-17 antagonists
KR102091294B1 (ko) * 2011-10-26 2020-04-16 암젠 인크 Uv 광으로의 노출로 인한 단백질 변형 및 분해의 감소 또는 제거 방법
BR112014010198B1 (pt) 2011-10-28 2022-12-06 Prothena Biosciences Limited Anticorpos humanizados que reconhecem alfa-sinucleína
US8790644B2 (en) 2012-01-27 2014-07-29 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
MX2015006997A (es) 2012-12-26 2015-09-23 Wockhardt Ltd Composicion farmaceutica.
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
ES2912729T3 (es) 2015-11-03 2022-05-27 Janssen Biotech Inc Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos
JP6992262B2 (ja) * 2016-03-31 2022-02-15 東ソー株式会社 変性抗体測定試薬の製造方法
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
AU2018359527A1 (en) 2017-10-31 2020-05-07 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CR20210435A (es) 2019-02-18 2021-09-20 Lilly Co Eli Formulación de anticuerpos terapéuticos

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
NZ530765A (en) * 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
EP3192528A1 (en) * 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
PL378812A1 (pl) * 2003-02-13 2006-05-29 Pfizer Products Inc. Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I
ES2527871T3 (es) * 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
JP4638870B2 (ja) * 2003-08-13 2011-02-23 ファイザー・プロダクツ・インク 修飾ヒトｉｇｆ−１ｒ抗体
CA2607663C (en) * 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
AU2006259536A1 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-IGF1R antibody formulations
RU2008142359A (ru) * 2006-03-28 2010-05-10 Ф.Хоффманн-Ля Рош Аг (Ch) Композиция человеческого моноклонального антитела к igf-1r

Also Published As

Publication number Publication date
TN2009000382A1 (en) 2010-12-31
US20100260766A1 (en) 2010-10-14
EP2136839A4 (en) 2010-04-07
MX2009010179A (es) 2010-03-15
UA96473C2 (ru) 2011-11-10
DOP2009000222A (es) 2009-12-15
CN101668540A (zh) 2010-03-10
IL200321A0 (en) 2010-04-29
CA2681743A1 (en) 2008-09-25
WO2008116103A2 (en) 2008-09-25
WO2008116103A3 (en) 2009-01-08
CR11005A (es) 2010-08-05
BRPI0809112A2 (pt) 2014-08-26
EA200970880A1 (ru) 2010-02-26
EP2136839A2 (en) 2009-12-30
ECSP099642A (es) 2009-11-30
KR20090113340A (ko) 2009-10-29
JP2010522208A (ja) 2010-07-01
AU2008228823A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
HUS2100038I1 (hu) Anti-CD20 antitest készítmények
HRP20182146T1 (hr) Formulacije protutijela natalizumab
IL200321A0 (en) Stable antibody formulations
HK1214947A1 (zh) 抗體製劑
EP2173163A4 (en) ANTIBODY FORMULATIONS
EP2077859A4 (en) ANTIBODY FORMULATION
SG10201604258YA (en) Anti-tnf antibody formulations
GB0711656D0 (en) Formulations
GB0716385D0 (en) Formulations
GB0712884D0 (en) Formulations
GB0711957D0 (en) Formulations
GB0809979D0 (en) Formulations
GB0810232D0 (en) Formulations
EP2167635A4 (en) ANTIBODY FORMULATIONS
GB0705179D0 (en) Formulations
GB0701993D0 (en) Formulations
GB0710900D0 (en) Formulations
GB0713886D0 (en) Formulations
GB0710346D0 (en) Formulations
GB0708663D0 (en) Formulations
GB0710350D0 (en) Formulations